All lobbying filings

CROSSROADS STRATEGIES, LLC

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · represents biopharmaceutical research companies

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Oct 18, 2025

Official filing document

Bills named in this filing 12

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S 832
EPIC Act of 2025
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
S 2296
National Defense Authorization Act for Fiscal Year 2026
HR 3838
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 20…
S 891
Bipartisan Health Care Act
S 527
Prescription Pricing for the People Act of 2025
S 1040
Drug Competition Enhancement Act
S 1041
Affordable Prescriptions for Patients Act
S 1097
Interagency Patent Coordination and Improvement Act of 2025
S 1095
Stop STALLING Act
S 1096
Preserve Access to Affordable Generics and Biosimilars Act

Lobbying activity 5

Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; drug pricing; Valued-Based Payments; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1492/S.832, EPIC Act of 2025.

Budget/Appropriations

H.R.1, One Big Beautiful Bill Act (P.L.119-21), all bio-pharmaceutical related provisions.

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Trade (domestic/foreign)

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

Health Issues

340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; antimicrobial resistance; insulin price cap; PBM reform; TRICARE Pharmacy Program (FY2026 National Defense Authorization Act, S.2296/H.R.3838); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interagency Patent Coordination and Improvement Act of 2025; S.1095, Stop STALLING Act; S.1096, Preserve Access to Affordable Generics and Biosimilars Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.